Abstract
Thyroid cancer is a common malignant tumor. Long non-coding RNA colon cancer-associated transcript 1 (lncRNA CCAT1) is highly expressed in many cancers; however, the molecular mechanism of CCAT1 in thyroid cancer remains unclear. Hence, this study aimed to investigate the effect of CCAT1 on human thyroid cancer cell line FTC-133. FTC-133 cells were transfected with CCAT1 expressing vector, CCAT1 shRNA, miR-143 mimic, and miR-143 inhibitor, respectively. After different treatments, cell viability, proliferation, migration, invasion, and apoptosis were measured. Moreover, the regulatory relationship of CCAT1 and miR-143, as well as miR-143 and VEGF were tested using dual-luciferase reporter assay. The relative expressions of CCAT1, miR-143, and VEGF were tested by qRT-PCR. The expressions of apoptosis-related factors and corresponding proteins in PI3K/AKT and MAPK pathways were analyzed using western blot analysis. The results suggested that CCAT1 was up-regulated in the FTC-133 cells. CCAT1 suppression decreased FTC-133 cell viability, proliferation, migration, invasion, and miR-143 expression, while it increased apoptosis and VEGF expression. CCAT1 might act as a competing endogenous RNA (ceRNA) for miR-143. Moreover, CCAT1 activated PI3K/AKT and MAPK signaling pathways through inhibition of miR-143. This study demonstrated that CCAT1 exhibited pro-proliferative and pro-metastasis functions on FTC-133 cells and activated PI3K/AKT and MAPK signaling pathways via down-regulation of miR-143. These findings will provide a possible target for clinical treatment of thyroid cancer.
Thyroid cancer; CCAT1; miR-143; VEGF; PI3K/AKT pathway; MAPK pathway
Retraction for: Braz J Med Biol Res | doi: http://10.1590/1414-431x20187046 | PMID: 29791590 | PMCID: PMC6002139
The authors would like to retract the article “lncRNA CCAT1 promotes cell proliferation, migration, and invasion by down-regulation of miR-143 in FTC-133 thyroid carcinoma cell line” that was published in volume 51 no. 6 (2018) (Epub May 21, 2018) in the Brazilian Journal of Medical and Biological Research.
After the publication of this study, the corresponding author requested its retraction due to “the identification of data fabrication.” The Editors decided to immediately retract this paper to avoid further damage to the scientific community.
The Brazilian Journal of Medical and Biological Research remains vigilant to prevent misconduct and reinforces the Journal’s commitment to good scientific practices. We regret the unprofessional behavior of the authors involved.
Correspondence: Ruihong Yan: <hongruiyan001@163.com> (new email)
Publication Dates
-
Publication in this collection
21 May 2018
History
-
Received
29 Aug 2017 -
Accepted
16 Feb 2018
